Intrathecal idursulfase‐ IT in children younger than 3 years with neuronopathic mucopolysaccharidosis II in a single‐arm, open‐label, phase 2/3 substudy and extension

Documenti analoghi

• Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase‐ IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis II
  di: Joseph Muenzer, et al.
  Pubblicazione: (2024)
• Treatment of Single Patient With PMM2 ‐Congenital Disorder of Glycosylation With Govorestat ( AT ‐007), an Aldose Reductase Inhibitor
  di: Elizabeth R. Jalazo, et al.
  Pubblicazione: (2025)
• Female Patients With Mucopolysaccharidosis II ( MPS II ): Insights From the Hunter Outcome Survey
  di: Barbara K. Burton, et al.
  Pubblicazione: (2025)
• Metabolic Control and Frequency of Clinical Monitoring Among Canadian Children With Phenylalanine Hydroxylase Deficiency: A Retrospective Cohort Study
  di: Nataliya Yuskiv, et al.
  Pubblicazione: (2025)
• Expanding the genetic and clinical spectrum of SLC25A42‐associated disorders and testing of pantothenic acid to improve CoA level in vitro
  di: Katharina Heckmann, et al.
  Pubblicazione: (2024)